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though the surgical technique was not as
defined in the protocol. We understand the
correspondents’ concern about possible se-
lection bias due to the exclusion of patients
who did not receive the correct graft or in
whom the surgeon did not target the correct
artery. However, such decision is logical
because it is not reasonable to assess the
patency of a radial graft when no such graft
exists. The same applies to assessing flow
to a vascular bed that was actually not
grafted. We consider that, in a study such
as this, angiographic analysis on “per-treat-
ment” principles is the correct approach.
We further note that this decision was
made a priori.
Finally, the conclusions of the article
are correct given the data available. Fur-
thermore, all the necessary information is
available in detail for readers to understand
the limitations that surround such conclu-
sions. There is no attempt to mislead and
whether our report will influence surgical
attitudes remains uncertain. Furthermore, it
is an “open verdict” and we cannot see how
it could jeopardize future randomized con-
trolled trials, given our conclusion that “the
continued evaluation of the RA is justi-
fied.” For our part, we are very committed
to carrying out good randomized trials in
cardiac surgery and will continue to do so
in a branch of medicine where, relatively
speaking, they are uncommon.
Rinaldo Bellomo, MD
Department of Intensive Care and Research
David L. Hare, MD
Department of Cardiology
Brian F. Buxton, MD
Department of Cardiac Surgery
Austin Hospital
Melbourne, Victoria, Australia
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Reply to the Editor:
The choice between the right internal tho-
racic artery (RITA) or radial artery (RA)
for the second coronary artery bypass con-
duit remains hotly debated, as evidenced
by 2 recent publications in the Journal, one
a randomized controlled trial1 and the other
a retrospective observational study.2
The interim 5-year result of our ran-
domized controlled study suggested that
the clinical outcomes of the RITA and the
RA groups were similar. This differed from
the conclusion drawn from the cohort study
reported by Caputo and colleagues,2 which
suggested a clinical benefit from using the
RA compared with the RITA. It is impor-
tant to consider possible reasons for such
an apparent difference in conclusions.
Caputo and colleagues’ study2 differed
from the randomized trial. There was no
assessment of graft patency, and they in-
cluded additional end points. Obviously,
cohort studies can never control for unrec-
ognized factors. Therefore, an observa-
tional study should always be regarded as
providing less reliable evidence than a ran-
domized trial.3 This has recently been
highlighted by the complete reversal of
opinion as to the benefits of hormone re-
placement therapy once the results of ran-
domized trials became available. One im-
portant factor that may not be well
controlled in an observational study of this
sort is the surgeon. The choice of graft was
“entirely at the discretion of the surgeon.”
If some surgeons strongly preferred one
type of operation, or even used it exclu-
sively, this means that the comparison
based on the observational data may suffer
from bias because of confounding with the
expertise of the surgeon.
Our comparison of cardiac event-free
survival in the randomized controlled trial
showed no significant differences, but this
does not necessarily mean that the 2 studies
are in conflict.
For our RA versus RITA comparison,
the estimates and 95% confidence intervals
(CIs) were 91% (76%-99%) for the RA
group and 82% (63%-99%) for the RITA
group. Because of the small numbers, these
CIs are very wide and therefore consistent
with a number of different possible under-
lying realities (“hypotheses”), namely, that
the RA and RITA have the same cardiac
event-free survival, that the RITA is better
than the RA, and that the RA is better than
the RITA. The latter is suggested by Ca-
puto and coworkers.2 Our study is not yet
in conflict with this because, for example,
our findings are consistent with a “true”
cardiac event-free survival of 90% for the
RA group and 70% for the RITA group;
both of these values are in the respective
CIs, and if they were the true values, which
they could be, that would be consistent
with Caputo and colleagues’ findings.
Biologically, the left internal thoracic
artery and RITA are similar and when
grafted to the left anterior descending and
circumflex coronary arteries4 have almost
identical results. However, when the RITA
is grafted to the right coronary system,
there is a significant reduction in patency.
For example, in the first 5 years of our
internal thoracic artery program from 1984
to 1989, patency of the in situ RITA graft
to the distal right coronary artery or its
branches was approximately 75%. Because
of the high graft failure rate of in situ RITA
grafts when used on the right side, most
surgeons, including ourselves, have fa-
vored using the RITA graft to the left sys-
tem,5 either as a free or in situ graft. This
latter strategy results in better graft survival
curves that separate by 6 years.6 Caputo
and coworkers,2 on the other hand, used an
in situ or pedicled graft in 94% of patients.
Furthermore, 53% of the RITA grafts were
attached to the right coronary or posterior
descending artery where results could be
less than optimal.2 Therefore, although
some of their analyses adjusted for the tar-
get artery and the authors thus claim that
the results were not compromised, it is not
clear whether adjustment was made for the
type of proximal anastomoses (in situ vs
free).
The clinical end point used by Caputo
and colleagues2 was a composite of death,
myocardial infarction, repeat coronary by-
pass or percutaneous coronary interven-
tion, and recurrent angina. Unfortunately,
any composite outcome measure is only as
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good as its weakest end point because all
outcomes are treated as having equal value.
It is no surprise that the composite end
point used by Caputo and colleagues is
largely dependent on the presence of recur-
rent angina, which is responsible for 31 of
43 clinical events in the RITA group and
10 of 15 clinical events in the RA group.
There were no objective criteria set for
diagnosing “recurrent angina,” which is al-
ways a difficult end point to assess in clin-
ical trials. The clinical wisdom and validity
of assigning the same statistical weight to
angina and death defy common sense, be-
cause most patients would value the 2 quite
differently.
The duration of follow-up in the study
of Caputo and colleagues2 is short, a me-
dian of 1.8 years for the patients receiving
a RITA graft and only 1.5 years for those
receiving an RA graft. It is clear that this is
a short-term study result and thus more
likely to reflect perioperative factors rather
than the development of graft disease.7 The
study is too short to make any long-term
conclusions. In our randomized trial,1 the
number of patients who had reached 5
years follow-up was relatively small, and
therefore longer-term conclusions are also
limited. A more appropriate conclusion for
the study of Caputo and colleagues would
be that, in the short term, the RITA used as
an in situ pedicle graft to the right coronary
system seems to result in an inferior clini-
cal outcome when compared with the RA.
Caputo and colleagues2 attempted to
control analytically for confounding fac-
tors. In the Cox proportional hazards model
for mortality, this means they were at-
tempting to adjust for other explanatory
variables with very small effective sample
sizes (1 death in the RA group and 5 deaths
in the RITA group). Such an analysis is
ambitious, to say the least. An alternative
form of analysis, which would probe the
comparability of the groups in terms of
their profiles, would be to use the propen-
sity score approach.8 This would model the
surgeon’s choice of operation in terms of
explanatory variables at the time of the
operation. It could show that there are non-
comparable subsets of the patient groups
and would more generally permit an anal-
ysis that more closely mimicked a random-
ized trial than analyses based on modeling
the outcomes in terms of all the explana-
tory variables.
In light of these observations, we be-
lieve that a more balanced conclusion
should have highlighted the limitations of
using composite outcomes to increase sta-
tistical power and raised the possibility that
an in situ RITA graft placed in the right
coronary system, at least in the short term,
might result in inferior results. It should
have also emphasized that these observa-
tions cannot be extrapolated to include free
RITA grafts (used in only 6% of patients)
or in situ RITA grafts placed in the left
system, where many remain patent for
more than 20 years.
There are satisfactory existing data to
guide current surgical practice, but obvi-
ously the long-term results from trials of
prospectively randomized patients are re-
quired.
Brian F. Buxton, MD
Rinaldo Bellomo, MD
Ian Gordon, PhD, AStat
David L. Hare, MD
Austin Hospital
Melbourne, Australia
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Reply to the Editor:
In this issue, Buxton and colleagues com-
ment on 2 recent articles in the Journal
reporting evidence about the effects of
choosing the right internal thoracic artery
(RITA) or radial artery (RA) for the second
arterial conduit for bypass grafting. The 2
articles reported interim results of a ran-
domized controlled trial (RCT)1 and a non-
randomized study (NRS).2
Buxton and colleagues advance several
alternative explanations to reconcile the ap-
parently conflicting findings of the two
studies: (1) There were differences in study
design, that is, the greater susceptibility, in
general, of observational data to bias. (2)
Specifically, there was the possibility of
inadequate control in the observational
study for differences between groups in
graft site and grafting strategy. (3) There
was a short duration of follow-up in the
observational study. (4) A composite out-
come (survival free from cardiac-related
events) was used in the observational
study. (5) The findings are, in fact, consis-
tent with one another given the imprecision
of the findings of both studies.
In the absence of data from well-con-
ducted RCTs with sufficient duration of
follow-up, it is not possible to distinguish
between these options; the last one is, argu-
ably, the most parsimonious. As we stated,2
such a trial is the only way to answer the
question, and Buxton and colleagues agree
with this point of view. However, the stated
suggestions raise a number of methodologic
points that may be of interest to readers.
The respective merits of RCTs and
NRSs are debated almost as “hotly” as
those of the RITA and RA.3 If an NRS of
an intervention suggests useful benefits for
patients, the intervention should be further
investigated in an RCT whenever possible.
RCTs and NRSs differ primarily with re-
spect to their susceptibility to selection
bias, leading to potential confounding.3 In
an NRS, the likely direction of confound-
ing can be inferred by inspecting the dis-
tribution of prognostic factors across
groups. If patients who received the appar-
ently more beneficial intervention had
more favorable prognostic characteristics,
then the finding may be explained by con-
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